Skip to content

A prospective study on defining the indications and clinical target volume (CTV) of prophylactic level IB in nasopharyngeal carcinoma

A prospective study on defining the indications and clinical target volume (CTV) of prophylactic level IB in nasopharyngeal carcinoma

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015880
Enrollment
Unknown
Registered
2018-04-26
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

nasopharyngeal carcinoma case series:prophylactic level IB irradiation

Sponsors

Jiangxi Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) histologically confirmed NPC by biopsy; (2) no evidence of distant metastasis; (3) receiving radical IMRT at initial diagnosis; (4) ECOG 0-2; (5) aged 18-70 years; (6) no pregnancy or lactation; (7) WBC= 4,000/ul, platelets= 100,000/ul; (8) Liver function:ALTAST < 1.5×ULNALP < 2.5×ULN,bilirubin< ULN; (9) serum creatinine= 1.6 mg/dl or 24hr. calculated creatinine clearance = 60ml/min; (10) Write consent form.

Exclusion criteria

Exclusion criteria: 1) WHO pathological classification for diversification squamous cell carcinomas and basal cell carcinoma; 2) Palliative treatment; 3) History of other malignant tumors; 4) Pregnancy or lactation women of child-bearing age women who consider the pregnancy test, during treatment in patients with effective contraception); 5) History of radiation therapy; 6) Local lymph node of chemotherapy or surgery (except diagnostic procedure); 7) Any serious and may bring risks to test or impact test compliance with diseases, such as unstable heart disease, kidney disease, need treatment of chronic hepatitis, poor blood sugar control of diabetes (> 1.5 x ULN) fasting glucose and emotional illness; 8) Pregnant women

Design outcomes

Primary

MeasureTime frame
relapse incidence of level IB lymph nodes;

Secondary

MeasureTime frame
Overall survival;

Countries

China

Contacts

Public ContactZeng Lei

Jiangxi Cancer Hospital

zlsports100@163.com+86 18870846505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026